NCT04060628|Unknown
Expanded Access to NanoDoce
1 other identifier
NANODOCE-EA
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredAug 2019
Brief Summary
NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 14, 2019
Completed5 days until next milestone
First Posted
Study publicly available on registry
August 19, 2019
CompletedLast Updated
January 23, 2026
Status Verified
January 1, 2026
First QC Date
August 14, 2019
Last Update Submit
January 21, 2026
Conditions
Interventions
Also known as: docetaxel
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- NanOlogy, LLClead
MeSH Terms
Conditions
Urogenital Neoplasms
Interventions
PowdersSuspensionsDocetaxel
Condition Hierarchy (Ancestors)
Neoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases
Intervention Hierarchy (Ancestors)
Dosage FormsPharmaceutical PreparationsColloidsComplex MixturesTaxoidsCyclodecanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsDiterpenesTerpenes
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 14, 2019
First Posted
August 19, 2019
Last Updated
January 23, 2026
Record last verified: 2026-01